[Congressional Record Volume 147, Number 115 (Thursday, September 6, 2001)]
[House]
[Pages H5448-H5450]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]
PROGRESS ON CURING PARKINSON'S DISEASE
The SPEAKER pro tempore. Under the Speaker's announced policy of
January 3, 2001, the gentleman from Colorado (Mr. Udall) is recognized
for 60 minutes as the designee of the minority leader.
Mr. UDALL of Colorado. Mr. Speaker, I come to the floor today to
commemorate the anniversary of the Morris K. Udall Parkinson's Disease
Research Act. This act, which was passed 4 years ago this month, has
strengthened our national research effort to develop more effective
treatments and hopefully a cure for Parkinson's disease.
Before I say what I have to say, I want to salute the millions of
people who are in the daily battle against this disease.
{time} 1700
I also want to thank Joan Samuelson and the Parkinson's Action
Network for their hard work on behalf of all of us.
Additionally, I want to take this opportunity to thank all of my
colleagues on the Congressional Parkinson's Working Group. To name a
few, the gentlewoman from New York (Mrs. Maloney), the gentleman from
Michigan (Mr. Upton), the gentleman from Illinois (Mr. Evans), and the
gentleman from New Mexico (Mr. Skeen); they have been on the front
lines in fighting for research dollars and holding various projects
accountable for the wise use of these funds.
Parkinson's is a devastating disease that affects more than 1 million
Americans and their families. Fifty thousand people are newly diagnosed
with Parkinson's each year, and of those with Parkinson's today,
roughly 40 percent are under the age of 60. Most of us know someone
with Parkinson's, or we know someone whose life has been touched by
Parkinson's. For some of us, this issue hits close to home.
Many people knew my dad, Mo Udall, and his story. He enjoyed great
health until 1976, when he broke both his arms in a fall off a ladder,
caught viral pneumonia, his appendix burst, he got peritonitis, and he
contracted Parkinson's Disease, all within 8 months. He had a long
battle with Parkinson's before he passed away in December of 1998.
One way my father chose to deal with Parkinson's was to make light of
it. Shortly after he was diagnosed, there was a scandal involving a
woman by the name of Paula Parkinson, a blond lobbyist who kissed and
told about her affairs with several Congressmen. He used to tell a joke
that there were two kinds of Parkinson's disease, the kind discovered
by an English doctor during the 1800s and the kind you get when you go
to Florida with a blond lobbyist. There were no similarities between
the two afflictions, he said, except they both cause you to lose sleep
and they both give you the shakes.
In all seriousness, though, I think Mo would be humbled and honored
by the fact that this important act and the centers of excellence it
creates are named after him. He dedicated his life to making a
difference in the lives of people, and by having his name associated
with this act, he continues to have an impact on the world even after
his death.
The act authorizes $100 million at the National Institutes of Health
for Parkinson's research. It also establishes 10 centers for research
throughout the Nation and creates a national Parkinson's information
clearinghouse for support of research and education.
Mr. Speaker, the Udall Act has helped us make tremendous progress in
the fight against Parkinson's and in understanding other
neurodegenerative diseases. That is why we need to act soon and
reauthorize the act. We need to give researchers the necessary funding
and support to combat this debilitating and ruthless disease.
We will be introducing legislation in the next month to reauthorize
the act, and I fervently hope that my colleagues will work with us to
make the dream of finding a cure for Parkinson's come true.
Mr. Speaker, at this time I would like to yield to my colleague and
good friend, the gentleman from the great State of North Carolina (Mr.
Price).
Mr. PRICE of North Carolina. Mr. Speaker, I thank the gentleman for
yielding to me and want to commend him for calling this Special Order
today and giving Members an opportunity to join in honoring the late
Morris Udall and in observing the fourth anniversary of the Morris K.
Udall Parkinson's Research Act.
Mr. Speaker, Parkinson's disease and related disorders afflict
approximately 1 million Americans. Sixty thousand more are diagnosed
each year with Parkinson's disease. Approximately 40 percent of those
afflicted are under the age of 60. This is a devastating disease, and
its incidence probably actually is underreported. Because it is not
contagious and it does not have to be reported, we probably
underestimate the extent of this devastating disorder. It is estimated
that Parkinson's disease costs society $25 billion or more annually.
I appreciate very much our colleague, the gentleman from Colorado
(Mr. Udall), coming to the floor today and sharing the story with his
colleagues of his father's illness; and of course, we all remember his
father's great accomplishments. Mo Udall was one of this body's
greatest Members in the 20th century, a man of great humor, great
concern for those in this society who are less fortunate, and a man of
great achievement in this body. Mo Udall's last years were marred by
Parkinson's disease, but he dealt with it courageously.
We are all fortunate that his son, our colleague from Colorado, and
his nephew, the gentleman from Arizona, are carrying on his good work
in this body. We appreciate what the gentleman from Colorado is doing
today and appreciate especially his sharing the story of his father
with us and reminding us of the importance of carrying on this work,
which we do in his name.
Mr. UDALL of Colorado. I thank the gentleman for expressing those
sentiments, and I know everyone in my family appreciates the affection
and respect that the gentleman has acknowledged that exists for my
father.
I would add to the comments that the gentleman made that I think
Parkinson's disease should truly be characterized as the most common
uncommon disease. And by that I mean, the researchers tell us only
about a million Americans have the disease. But I guarantee that if we
were to walk out on the streets outside the Capitol here and we were to
talk to four or five people, by the time we would get to the fifth
person, they will know somebody in their immediate family or a friend
who has Parkinson's disease and who is battling it valiantly.
They would also, I think, be excited to know that we are so close to
not only finding ways to combat the disease but to actually identify a
cure, and that is why it is so important to reauthorize this act and
continue the momentum that has been generated over the past 10 years.
Mr. PRICE of North Carolina. That is absolutely true. The number of
families affected by this disease directly and indirectly is, of
course, in the millions, and that includes my own family. My late
father had a brother who was afflicted with Parkinson's. He had an
uncle who was afflicted with Parkinson's.
My dad, incidentally, was a great fan of the gentleman's father. I
remember when I was the Democratic Party chairman in North Carolina, we
were fortunate enough to line up Mo Udall as the speaker at our annual
party banquet. It was over in the western part of the State, so my dad,
who resided in east Tennessee, was able to come over for this function.
He could not stop laughing. He said Mo Udall was the funniest man he
had ever heard or seen anywhere, almost enough to make a Democrat out
of him!
Mo Udall was a wonderful man who brought great good humor to
politics, great warmth, and a wonderful spirit. He later autographed
his book ``Too Funny to Be President,'' and we gave it
[[Page H5449]]
to my dad to his great delight. So Mo Udall was a huge personal
favorite in our family.
One cannot imagine a more fitting monument, a more fitting tribute to
Mo Udall, than to pass this research act aimed at the scourge of
Parkinson's disease and to carry out this path-breaking research in Mo
Udall's name.
The gentleman, of course, is quite accurate also in depicting the
promise of this research. We have now across the country 11 Morris K.
Udall Parkinson's Research Centers. One of those is at Duke University
in my part of North Carolina. Dr. Jeffery Vance leads the Udall Center
at Duke University, where a research team is using several state-of-
the-art methods to find genes that may contribute to the etiology of
Parkinson's disease and to distinguish the genes that contribute to
familial Parkinson's from those involved in sporadic cases. That is
path-breaking research, typical of what is going on in these research
centers.
The Udall program also has expanded basic and clinical research at
institutions across this country. It has established the Morris K.
Udall awards to encourage innovative research, and supported the
creation of Parkinson's data banks and information clearinghouses in
support of research and education.
So this is a landmark statute and the programs that it has spawned
are ongoing and are full of promise. It is very, very important not
only to observe this fourth anniversary of the Udall Act's passage, but
also to pledge here and now that we are going to continue this work and
build on this work.
We must double the NIH's budget over these 5 years, and I hope and
believe we are on the way to doing that in this year's appropriations
cycle. NIH has developed, under the directions laid down by the Udall
Act, a 5-year Parkinson's disease research agenda. Last year, Congress
funded the first year of that plan, so within NIH it is vitally
important to continue that specific research program.
The Udall Act has gotten us started, and it has provided the
framework for the comprehensive research that we simply must undertake
as a Nation on Parkinson's disease. And I would say to the gentleman
that I hope, in having this Special Order today and observing this
fourth anniversary, that this can be an occasion for all of us, all of
our colleagues, to resolve to continue to build upon the vital and
necessary work that the Udall Act has gotten under way.
Mr. UDALL of Colorado. If I might add an additional comment, I am
confident that our colleagues on both sides of the aisle will join us
in this important effort to reauthorize this piece of legislation.
Parkinson's is not a Republican or a Democrat or a Green Party
or Libertarian Party disease. It affects people across our country and
across the world. And the work that has been done, as the gentleman
points out, is far-reaching. And we are so close to understanding how
to not only, as I mentioned earlier, make sure that the disease is
mitigated but literally cured.
The area of the brain where this takes place has been identified and
mapped. And as the gentleman points out, there are indications that the
disease is, in some cases, genetic or hereditary; but in other cases,
is environmentally induced. There is excellent work going on in the
Department of Defense also, working with veterans, and they are looking
through their own program on how to combat Parkinson's disease or
contributing to the efforts at NIH has undertaken.
I want to again thank the gentleman for taking his time to come to
the floor and to point out to our colleagues the great opportunity we
have to make a difference in a lot of lives. If we think about a
million Americans who have the disease, think about the extended
families that are affected by the disease and the costs that are
incurred, not just financially, but emotionally, in these communities,
this is a terrible disease; and it is one that we can cure and we ought
to get about the business of it now.
So I thank the gentleman.
Mr. PRICE of North Carolina. I thank the gentleman from Colorado for
his comments here today and for carrying on this great work. We must
use this occasion to resolve to press forward.
Mr. UDALL of Colorado. I thank the gentleman for joining us today.
It is my pleasure at this point to yield time to my colleague, the
gentleman from the great State of Rhode Island (Mr. Langevin).
(Mr. LANGEVIN asked and was given permission to revise and extend his
remarks.)
Mr. LANGEVIN. Mr. Speaker, I wish to thank my colleague, the
gentleman from Colorado, for yielding time for me to speak on this
issue. Before I begin, I want to mention that, of course, I never had
the opportunity to meet his father, Mo Udall, but I have nothing but
respect for the reputation that he has established in public service,
and I know that he would be proud of his son, the gentleman from
Colorado, in continuing that proud family tradition of strong
commitment to public service.
Mr. Speaker, I rise today to honor the fourth anniversary of the
passage of the Morris K. Udall Parkinson's Research Act and to stress
the vital importance of expanding support and research for treatment of
Parkinson's disease. Named for Arizona Representative Mo Udall, the
Parkinson's Research Act expands basic and clinical research on
Parkinson's disease and establishes Morris K. Udall Centers for awards
for excellence in Parkinson's disease research.
Since its introduction, this landmark legislation has received
overwhelming congressional support. In the 105th Congress, the Morris
K. Udall Parkinson's Research Act garnered 255 cosponsors, and in the
106th Congress it passed the Senate by a nearly unanimous vote of 95 to
3.
I am proud that Congress embraced this initiative, as more people
suffer from Parkinson's disease than multiple sclerosis, muscular
dystrophy and Lou Gehrig's disease combined.
{time} 1715
But our work is far from over. About 60,000 Americans are diagnosed
with this disease each year, that is one person every 9 minutes, and
more than half a million living with Parkinson's disease today.
Fortunately, there may be some hope on the horizon. Parkinson's
disease is one of the many diseases for which stem cell research offers
significant promise. Yesterday I testified before the Senate Health,
Education, Labor and Pensions Committee about the potential for
embryonic stem cell research to alleviate pain and suffering in
millions of people. It is my strong hope that our Nation's premier
researchers will be able to engage in this ground-breaking research
expeditiously to save, lengthen, and dramatically improve the quality
of life of those who live with Parkinson's and other debilitating
diseases and conditions.
On this anniversary of the Morris K. Udall Parkinson's Research Act,
I urge my colleagues to follow through on our commitment to double the
budget of the National Institutes of Health, increase funding for the
Morris K. Udall Center, and break down the barriers to unprecedented,
life-saving stem cell research. Until we have conquered Parkinson's,
our work is not complete.
Mr. UDALL of Colorado. Mr. Speaker, I thank my colleague for taking
the time to come speak on this important issue; and I want to associate
myself with his comments on stem cell research.
Stem cell research is an important part of understanding Parkinson's
disease and eventually finding a cure. I look forward to working with
the gentleman in the days and months and years to come to see that that
promise is fulfilled. I thank the gentleman for taking the time to join
us today.
Mr. Speaker, I yield to the gentlewoman from the State of Texas (Ms.
Jackson-Lee).
Ms. JACKSON-LEE of Texas. Mr. Speaker, I thank the gentleman from
Colorado (Mr. Udall), one, for his vision, for his family, and for this
very special legislation of the day to honor the authorization, the
fourth anniversary of the authorization and passage of the Morris K.
Udall Parkinson's Research Act. This is an important anniversary.
Throughout our tenure in Congress there are ups and downs. What I
consider an up is an opportunity to meet with my constituents from my
district and all over the Nation. Some of the most eloquent and
articulate persons
[[Page H5450]]
are those who are physically suffering from Parkinson's and others who
come to collaborate on the importance of finding a cure and the ability
to research this debilitating disease.
In the name of Morris K. Udall, this legislation passed an important
milestone in striking a chord for finding out the reason that this
disease has gotten such a grip on people around the world. This
research or this research act has been funded and the legislation, of
course, was passed through the leadership of Senator Wellstone in terms
of adding an amendment and adding additional dollars. We now come to a
time where it is necessary to reauthorize it.
Even more so during this stem cell research debate that I find the
importance of this particular legislation which continually persists in
attempting to find a cure by added research. It never allows to rest
the continued theorizing and study of the importance of discovering new
ways to attack this disease.
I am certainly disappointed that we are at a certain standstill in
stem cell research. I would have wanted and do want the President to go
further. I believe that he was well-intentioned but may be misadvised
by those who would think that we had enough of the research elements
that could do the vast massive research that needs to be done. This
research act has shown that the broader, the better, the fuller, the
better.
Let me congratulate the gentleman on the number of centers that
already exist. We look forward to helping the funding expand, not
frivolously, but so that centers could be expanded across the country.
I would certainly welcome one in Houston, Texas.
Mr. Speaker, let me thank the gentleman for, one, having the insight
to be at the forefront of the reauthorization of this legislation. Let
me also say that I would willingly join as an original co-sponsor of
this legislation and offer to say to those who have been suffering from
Parkinson's for time before and today and tomorrow that we will
continue to fight until we can find a cure.
Mr. UDALL of Colorado. Mr. Speaker, I thank my colleague for her
remarks and for her vision as well.
Mr. Speaker, in conclusion, I would like to urge all of the Members
of this body to join us in a bipartisan fashion when we introduce this
legislation in the next couple of weeks to reauthorize the Udall Act.
I want to thank, in particular, the gentleman from Michigan (Mr.
Upton), the gentleman from New Mexico (Mr. Skeen), the gentleman from
Illinois (Mr. Evans), and the gentlewoman from New York (Mrs. Maloney)
for their support and hard work on behalf of all the people and all the
families who suffer from Parkinson's disease. I know we will do the
right thing in this body and reauthorize this very, very important act
and we can all be proud when we find the cure for Parkinson's sooner
rather than later.
Mr. WAXMAN. Mr. Speaker, I rise today in recognition of the fourth
anniversary of the passage of the Morris K. Udall Parkinson's Research
Act. I cannot think of a more fitting tribute to my friend and
colleague than this legislation.
Mo Udall was a member of the House Representatives for thirty years
from 1961-1990. He earned the respect of all who served with him
through his humor and civility as well as his ability to work with
Members from both sides of the aisle. Mo's courage and determination to
continue to serve even after being diagnosed with Parkinson's disease
in 1978 was an inspiration for all who had the privilege to be around
him during that time. He was determined to continue to lead a full and
vigorous life even in the face of this debilitating disease. Although
his death in 1998 was a blow to all of us, his legacy lives on in the
great and important work started through this legislation.
Mr. Speaker, Parkinson's disease afflicts 1 million Americans, 40
percent of whom are under the age of 60. This landmark legislation
dramatically expanded and coordinated clinical research into
Parkinson's disease as well as established the Morris K. Udall Centers
across the country. These centers have been an invaluable resource in
the fight against Parkinson's disease. They have provided state-of-the-
art training facilities for new researchers and the resulting work has
greatly increased our knowledge and understanding of the disease.
We have an opportunity and an obligation today to rededicate
ourselves to the goal of finding a cure for Parkinson's disease. Our
initial investment into research four years ago has yielded impressive
returns. Still, however, much more needs to be done. Mr. Speaker, I
call on Congress to continue the valuable work we started four years
ago and fully fund federal research into Parkinson's disease done by
the National Institutes of Health and the Morris K. Udall Centers.
Mr. SKEEN. Mr. Speaker, I commemorate today the anniversary of the
Morris K. Udall Parkinson's Research Act, and I am pleased to be here
among other champions of the cause from the Parkinson's Working Group
here in the House.
Mo Udall was more than a colleague. He was a friend. We didn't always
agree on politics, but we could always share a laugh. I remember flying
him around on my plane in NM. And, I remember helping to pick up his
papers when they fell to the ground in the Interior Committee.
But, this anniversary honors more than Mo Udall. It honors our
commitment to helping science keep it's promise. It has been more than
fifteen years since America began to hear that a cure for Parkinson's
was just around the corner, . . . perhaps just five years away. Yet it
is not here yet. This Udall Act of 1997 was the first time we put the
money where science's mouth was. Thanks to NIH, the U.S. Army, Udall
Centers of Excellence, and private research carried on largely thanks
to an outstanding advocacy community, we are still on target.
As this Anniversary hits . . . it also marks the sunset of the bill.
Perhaps it is time we reauthorize it. Let us continue to help science
keep its promise. Thank you.
Mr. EVANS. Mr. Speaker, we are here today to honor the memory of one
of our great former colleagues, the late Mo Udall, who served in this
House for nearly three decades. Four years ago this week, Congress
passed the Morris K. Udall Parkinson's Disease Research Act as a
tribute to his service and the courage that he displayed in the face of
his illness. Sadly, Mo lost his battle with Parkinson's Disease in
1998. But his memory lives on in this Congress and in the research labs
across the country that bear his name.
I served with Mo Udall from 1983 to his retirement in 1990. During
those years, I came to know and admire him as an effective legislator,
a consummate humorist, and a dear friend. Mo always had a kind word and
a joke for everyone. He brought a levity to this body that you wouldn't
expect from someone fighting for his life. Ask anyone here who had the
pleasure to serve with Mo and they will have a side splitting tale of
the time that Mo brought the house down. Coupled with his good humor,
was a commitment to serve this nation well. Despite his Parkinston's
Disease, he served as chairman of the Interior Committee where he was a
champion of preserving America's widerness areas. I admired Mo then,
but my esteem for him grew even greater when I was diagnosed with
Parkinston's Disease ins 1995.
Our purpose here is to commemorate the passage of the Udall Act,
which brings much needed resources to the study of Parkinson's Disease.
The time has come to reauthorize the bill. And today, we have the honor
of being joined by Mo's son, Congressman Mark Udall, who will lead the
charge to see this program continued. We will be introducing the
reauthorization bill in the coming month. I hope that all of our
colleagues will join us in supporting that bill.
The 11 Morris K. Udall Centers are busy conducting research on every
aspect of Parkinson's Disease. The scientists there are some of the
best and the brightest in their field. They believe that a cure for
Parkinson's Disease is on the horizon--that it could be discovered in
as littlle as five years. These researching give me hope. They are out
there everyday working to make my life and the lives of the one million
Americans living with Parkinson's Disease better. And let me tell you--
it's nice having these bright men and women on your side. I know they
will find a cure, but they can't do it without our continued support.
These Udall Centers are just one component of a larger effort on the
part of NIH to develop more effective treatments, enhance prevention
efforts, and eventually find a cure of Parkinson's Disease. At the
request of Congress, NIH developed a five year Parkinson's Disease
Research Agenda to bring the nation closer to a cure. Last year, we
funded the first year of that agenda. This year, we must fund the
second year by increasing funding for Parkinson's Disease research by
$143 million. I am hopeful that the Appropriations Committee will
follow through with what it started and honor Congress' commitment to
the NIH Research Agenda.
These initiatives are the lifeblood of the Parkinson's community. The
Udall Centers and the NIH funded research are leading the world in the
path to a cure. I encourage my colleagues support these programs.
____________________